Welcome to our dedicated page for CATALENT news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on CATALENT stock.
Catalent, Inc. (symbol: CTLT) is a leading contract development and manufacturing organization (CDMO) that plays a crucial role in the global pharmaceutical and biotechnology industries. With over 80 years of experience, Catalent specializes in providing a comprehensive range of development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company operates under four main segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
At Catalent, innovation and expertise are at the core of their operations. The company is dedicated to accelerating the development and delivery of new treatments by leveraging its advanced technologies and extensive industry knowledge. Catalent's services span the entire lifecycle of a product, from initial drug development and clinical trials to commercial manufacturing and packaging. This end-to-end approach allows them to support pharmaceutical customers with long-term supply agreements and partnerships.
One of Catalent's key strengths lies in its global presence. The company operates over 50 state-of-the-art facilities across four continents, ensuring that it can meet the diverse needs of its clients worldwide. By providing tailored solutions and maintaining high standards of quality and reliability, Catalent has established itself as a trusted partner for many of the world's leading pharmaceutical companies.
Catalent's commitment to innovation is evident through its focus on drug delivery technologies. As a world leader in this field, the company has a proven track record of enhancing bioavailability, solubility, and permeability of drug compounds. These advancements not only improve the efficacy of treatments but also enhance patient compliance and outcomes. Catalent's expertise in developing more effective and convenient drug delivery methods has made a significant impact on the healthcare industry.
Financially, Catalent remains robust, with consistent revenue generation driven by its long-term contracts and diverse service offerings. The company's ability to adapt to market demands and invest in cutting-edge technologies has positioned it for sustained growth. Recent achievements include the expansion of their biologics capabilities and strategic collaborations with key industry players to advance cell and gene therapies.
In conclusion, Catalent, Inc. stands as a pivotal entity in the pharmaceutical and biotechnology sectors. Through their extensive range of services, global reach, and unwavering commitment to innovation, they continue to drive faster, more efficient development timelines and deliver superior manufacturing and packaging solutions. For investors and stakeholders, Catalent represents a vital player in the advancement of modern medicine and healthcare.
Catalent Inc. (NYSE: CTLT) announced its acquisition of Bettera Holdings, LLC for $1 billion. This strategic move will enhance Catalent's offerings in the nutritional supplements market, particularly in gummy, soft chew, and lozenge segments. The acquisition is expected to close by year-end 2021 and includes Bettera’s production facilities across the U.S. The merger aims to leverage both companies' capabilities to provide advanced solutions in consumer health and beauty, unlocking significant synergies. Catalent plans to fund the acquisition through cash and existing credit facilities.
Catalent, Inc. (NYSE: CTLT) reported Q4'21 net revenue of $1.19 billion, a 25% increase from Q4'20, driven by a 26% organic revenue growth. Fiscal 2021 net revenue reached $4.00 billion, up 29% year-over-year. Q4'21 net earnings were $182 million, with an adjusted EBITDA of $348 million. The company announced a proposed $1 billion acquisition of Bettera, enhancing its position in nutritional supplements. For FY'22, it projects net revenue growth of 8-13% and Adjusted EBITDA growth of 11-18%.
Catalent, Inc. (NYSE: CTLT) will release its fourth-quarter financial results for fiscal year 2021, which ended June 30, 2021, on August 30, 2021, before market open. A management webcast will follow at 8:15 a.m. ET to discuss these results. Investors can access the webcast through Catalent’s website. A supplemental slide presentation will also be available for review prior to the webcast and will be accessible for 90 days post-event.
Catalent, Inc. (NYSE: CTLT) announced that as of July 1, 2021, 97% of its electricity usage is sourced from renewable energy, including wind, solar, hydroelectric, and biomass. This move is part of Catalent's commitment to sustainability, aligning with their agreement with the Science-Based Target initiative (SBTi) to set greenhouse gas emission reduction goals. The CEO, John Chiminski, emphasized the importance of this progress for the biopharma sector's long-term sustainability and environmental strategy.
Catalent, Inc. (NYSE: CTLT) announced that its Chair and CEO, John Chiminski, will present virtually at the Biopharma CEO Investor Forum on June 8, 2021, at 9:45 a.m. ET. The presentation will be available via a live webcast and can be replayed afterward. Catalent is a prominent global provider focused on advanced delivery technologies and manufacturing solutions across various sectors, including drugs and biologics. With over 85 years of experience and more than $3 billion in revenue for fiscal year 2020, Catalent employs over 15,000 staff worldwide.
Catalent, Inc. (NYSE: CTLT), a leading provider of advanced delivery technologies, announced that its executive leadership team will present virtually at two upcoming conferences. The presentations are scheduled for June 1, 2021, at the Jefferies Healthcare Conference at 10:30 a.m. ET, and June 3, 2021, at the William Blair 41st Annual Growth Stock Conference at 11:40 a.m. ET. A live webcast of the events will be available at investor.catalent.com and can be replayed afterwards.
Catalent, Inc. (NYSE: CTLT), a global leader in advanced delivery technologies and manufacturing solutions, will present virtually at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 11:00 a.m. ET. The presentation will be available for live streaming and replay on their investor website. With over 85 years of experience, Catalent specializes in bringing drugs, biologics, and consumer health products to market efficiently, generating over $3 billion in revenue in FY 2020, and employing over 14,000 staff across 40 facilities worldwide.
Catalent, Inc. (NYSE: CTLT) has released its Corporate Responsibility (CR) Report for fiscal year 2020, highlighting its commitment to sustainability amidst the COVID-19 pandemic. The report outlines progress in energy efficiency, diversity, and community investments, with a goal for all sites to achieve wastewater discharge standards by fiscal 2024. Key achievements include the completion of 50 energy efficiency projects and six sites transitioning to renewable electricity. The company also addressed workforce well-being and expanded its community initiatives, benefiting 500 non-profits during the fiscal year.
Catalent, Inc. (NYSE: CTLT) has appointed Thomas Castellano as Senior Vice President and Chief Financial Officer, effective June 1, 2021. He succeeds Wetteny Joseph, who is leaving to join Zoetis Inc. Castellano, a long-term employee with over 13 years at Catalent, has held several senior financial roles, most recently as Global Vice President of Operational Finance. The Board expressed gratitude to Joseph for his service and praised Castellano's contributions, highlighting the company’s effective succession planning and strong leadership development.
Catalent, Inc. (NYSE: CTLT), a global leader in advanced delivery technologies and manufacturing solutions, will present at the BofA Securities 2021 Health Care Conference on May 12, 2021, at 11:45 a.m. ET. The presentation will be available via live webcast on their investor site, with a replay option afterward. Catalent has over 85 years of industry experience, employs more than 14,000 staff, including 2,400 scientists, and generated over $3 billion in revenue in fiscal 2020. The company is headquartered in Somerset, New Jersey.
FAQ
What is the current stock price of CATALENT (CTLT)?
What is the market cap of CATALENT (CTLT)?
What is Catalent, Inc.'s core business?
How many facilities does Catalent operate?
What segments does Catalent operate under?
What is Catalent known for in drug delivery technologies?
Who are Catalent's primary customers?
What recent achievements has Catalent made?
How does Catalent support drug development?
What distinguishes Catalent in the pharmaceutical industry?
What is the significance of Catalent's global presence?
How does Catalent ensure the quality of their services?
